PMID- 11035985
OWN - NLM
STAT- MEDLINE
DCOM- 20001116
LR  - 20191104
IS  - 0091-6765 (Print)
IS  - 0091-6765 (Linking)
VI  - 108 Suppl 5
DP  - 2000 Oct
TI  - Immunohistochemical localization of growth factors and their receptors in uterine 
      leiomyomas and matched myometrium.
PG  - 795-802
AB  - Immunolocalization of transforming growth factor alpha (TGF-Alpha), epidermal 
      growth factor (EGF), insulinlike growth factor (IGF)-I, vascular endothelial 
      growth factor (VEGF(165,189,121)), basic fibroblast growth factor (FGF)-2, EGF 
      receptor (R), IGF-IRbeta, and FGFR-1 was studied in uterine leiomyomas and 
      matched myometrial samples taken from seven women (42-47 years of age) in the 
      proliferative phase of the menstrual cycle. Immunolocalization of growth factor 
      peptides was accomplished with either monoclonal or polyclonal antibodies to the 
      amino or carboxy terminus of growth factor peptides or their respective 
      receptors, or against full-length recombinant growth factor. All reactions were 
      conducted using the avidin-biotin complex method. Immunolocalization of 
      TGF-alpha, EGF, EGF-R, IGF-I, IGF-IRbeta, FGF-2, FGFR-1, and VEGF was observed in 
      the cytoplasm of smooth-muscle cells of leiomyomas and matched myometrium. The 
      cytoplasm of vascular smooth-muscle cells expressed TGF-alpha, EGF, EGF-R, IGF-I, 
      IGF-IRbeta, FGF-2, FGFR-1, and VEGF, whereas the vascular endothelium was 
      positive for TGF-alpha, EGF, EGF-R, FGF-2, and FGFR-1 in both leiomyomas and 
      matched myometria. Fibroblasts within the fibrous component of some leiomyomas 
      were positive for IGF-I and FGF-2 and minimally positive for FGFR-1. In addition, 
      the extracellular matrix of leiomyomas showed focal localization of FGF-2 and 
      IGF-I in some tumors. When scores of intensity and percent positive staining were 
      compared, IGF-IRbeta was significantly increased in the leiomyomas compared to 
      matched myometria, whereas EGF was significantly decreased in the uterine 
      leiomyomas compared to matched myometria. In summary, these data revealed growth 
      factors to be expressed differentially in smooth muscle, vascular and 
      fibroblastic cell types of leiomyomas and matched myometria. Specifically, 
      IGF-IRbeta was significantly increased in leiomyomas; although a similar increase 
      was seen with IGF-I peptide, statistical significance was not achieved. The EGF 
      peptide was significantly decreased in the leiomyomas compared to matched 
      myometrium. These data suggest that IGF-IRbeta and IGF-I peptide may be one of 
      several growth factor/receptor pathways important in uterine leiomyoma growth 
      during the proliferative phase of the menstrual cycle. In addition, decreased EGF 
      may be secondary to the predominant estrogenic milieu present at time of 
      sampling, as it has been proposed that progesterone, and not estrogen, may 
      regulate EGF.
FAU - Dixon, D
AU  - Dixon D
AD  - Laboratory of Experimental Pathology, National Institute of Environmental Health 
      Sciences, Research Triangle Park, North Carolina 27709, USA. dixon@niehs.nih.gov
FAU - He, H
AU  - He H
FAU - Haseman, J K
AU  - Haseman JK
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Environ Health Perspect
JT  - Environmental health perspectives
JID - 0330411
RN  - 0 (Endothelial Growth Factors)
RN  - 0 (Growth Substances)
RN  - 0 (Lymphokines)
RN  - 0 (Receptor, IGF Type 2)
RN  - 0 (Receptors, Fibroblast Growth Factor)
RN  - 0 (Receptors, Growth Factor)
RN  - 0 (Somatomedins)
RN  - 0 (Transforming Growth Factor alpha)
RN  - 0 (VEGFA protein, human)
RN  - 0 (Vascular Endothelial Growth Factor A)
RN  - 0 (Vascular Endothelial Growth Factors)
RN  - 103107-01-3 (Fibroblast Growth Factor 2)
RN  - 62229-50-9 (Epidermal Growth Factor)
RN  - EC 2.7.10.1 (ErbB Receptors)
RN  - EC 2.7.10.1 (FGFR1 protein, human)
RN  - EC 2.7.10.1 (Receptor Protein-Tyrosine Kinases)
RN  - EC 2.7.10.1 (Receptor, Fibroblast Growth Factor, Type 1)
SB  - IM
MH  - Adult
MH  - Case-Control Studies
MH  - Endothelial Growth Factors/analysis
MH  - Epidermal Growth Factor/analysis
MH  - ErbB Receptors/analysis
MH  - Female
MH  - Fibroblast Growth Factor 2/analysis
MH  - Growth Substances/*analysis
MH  - Humans
MH  - Immunohistochemistry
MH  - Leiomyoma/*pathology
MH  - Lymphokines/analysis
MH  - Menstrual Cycle/physiology
MH  - Middle Aged
MH  - Receptor Protein-Tyrosine Kinases/analysis
MH  - Receptor, Fibroblast Growth Factor, Type 1
MH  - Receptor, IGF Type 2/analysis
MH  - Receptors, Fibroblast Growth Factor/analysis
MH  - Receptors, Growth Factor/*analysis
MH  - Somatomedins/analysis
MH  - Transforming Growth Factor alpha/analysis
MH  - Uterine Neoplasms/*pathology
MH  - Vascular Endothelial Growth Factor A
MH  - Vascular Endothelial Growth Factors
EDAT- 2000/10/19 11:00
MHDA- 2001/02/28 10:01
CRDT- 2000/10/19 11:00
PHST- 2000/10/19 11:00 [pubmed]
PHST- 2001/02/28 10:01 [medline]
PHST- 2000/10/19 11:00 [entrez]
AID - sc271_5_1835 [pii]
AID - 10.1289/ehp.00108s5795 [doi]
PST - ppublish
SO  - Environ Health Perspect. 2000 Oct;108 Suppl 5:795-802. doi: 
      10.1289/ehp.00108s5795.